Development of complementary and alternative medicine approaches to liver disease is a priority area at NCCAM. Minimal hepatic encephalopathy (MHE) is a significant complication of cirrhosis which can result in poor quality of life, impaired cognition and difficulty in driving motor vehicles with a high traffic accident risk. MHE is estimated to affect one half of the 5.5 million cirrhotics in the U.S. Despite these negative outcomes, there is no consensus on treatment of MHE. Currently available therapies for MHE act on intestinal flora but are limited by adverse effects (i.e. lactulose-induced diarrhea), which negatively impact adherence. Probiotic bacterial supplements, which also act on intestinal flora, are an emerging therapy for MHE. Our group has performed a pilot, randomized trial which demonstrated a significantly higher rate of MHE reversal with excellent adherence in patients randomized to probiotic yogurt compared to no therapy. This proposal intends to define Lactobacillus GG (LGG) as a biologically-based alternative therapy for MHE with special focus on metabolic and stool bacteriologic changes. The hypothesis of this Phase I proposal is: LGG will be safe and efficacious for the treatment of minimal hepatic encephalopathy compared to placebo in a randomized, double-blind trial. This will be carried out with four specific aims.
Specific aim 1 : To define the safety and tolerability of LGG in patients with minimal hepatic encephalopathy against placebo in a Phase I randomized controlled trial.
Specific aim 2 : To define the effect of LGG on intestinal microflora composition in cirrhotics with minimal hepatic encephalopathy using 16s stool DNA sequencing in a randomized, placebo-controlled trial.
Specific aim 3 : To determine the effect of LGG on metabolic biomarkers and cytokines in stool, urine and blood using nuclear magnetic resonance spectroscopy in minimal hepatic encephalopathy.
Specific aim 4 : To determine the effect of LGG on psychometric function in patients with minimal hepatic encephalopathy.
The specific aim and sub-aims will be tested in 40 patients with non-alcoholic cirrhosis and MHE: 20 randomized to LGG and 20 randomized to placebo to be taken BID for 8 weeks with detailed psychometric, metabolic, anthropometric and bacteriologic evaluation. Results generated from this study will form the basis for a RO1 proposal to develop the use of probiotics as a biologically-based alternative treatment with long-term outcomes of prognosis, development of overt encephalopathy and prevention of traffic accidents in patients with MHE.

National Institute of Health (NIH)
National Center for Complementary & Alternative Medicine (NCCAM)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAT1-JH (25))
Program Officer
Duffy, Linda C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Bajaj, J S; Heuman, D M; Hylemon, P B et al. (2014) Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39:1113-25
Ahluwalia, Vishwadeep; Wade, James B; Heuman, Douglas M et al. (2014) Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis 29:1017-25
Kakiyama, Genta; Muto, Akina; Takei, Hajime et al. (2014) A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J Lipid Res 55:978-90
Bajaj, Jasmohan S; Heuman, Douglas M; Hylemon, Phillip B et al. (2014) Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60:940-7
Bajaj, Jasmohan S; Thacker, Leroy R; Heuman, Douglas M et al. (2013) The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 58:1122-32
Kakiyama, Genta; Pandak, William M; Gillevet, Patrick M et al. (2013) Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 58:949-55
Bajaj, Jasmohan S; Ahluwalia, Vishwadeep; Wade, James B et al. (2013) Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol 58:38-44
Bajaj, Jasmohan S; Riggio, Oliviero; Allampati, Sanath et al. (2013) Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol 11:1511-6
Bajaj, Jasmohan S; Heuman, Douglas M; Sanyal, Arun J et al. (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8:e60042
Ahluwalia, Vishwadeep; Wade, James B; Thacker, Leroy et al. (2013) Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 59:467-73

Showing the most recent 10 out of 19 publications